Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
No open-market purchases or sales by Maxcyte, Inc. insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $78.0M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Maxcyte, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +11 vs. Q4 2022
- Shares held
- 66.6M
- −2.23M (−3.2%) vs. Q4 2022
- Total value
- $327.9M
- −$47.4M (−12.6%) vs. Q4 2022
- New holders
- 16
- 52 more added
- Sold out
- 5
- 28 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MXCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 122 | $78.0M |
| Q1 2026 | 132 | $46.2M |
| Q4 2025 | 112 | $98.0M |
| Q3 2025 | 112 | $110.8M |
| Q2 2025 | 120 | $155.5M |
| Q1 2025 | 115 | $193.8M |
| Q4 2024 | 119 | $301.9M |
| Q3 2024 | 120 | $267.4M |
| Q2 2024 | 114 | $268.0M |
| Q1 2024 | 124 | $280.8M |
| Q4 2023 | 121 | $316.1M |
| Q3 2023 | 120 | $200.8M |
| Q2 2023 | 116 | $303.3M |
| Q1 2023 | 115 | $327.9M |
| Q4 2022 | 105 | $377.7M |
| Q3 2022 | 109 | $453.8M |
| Q2 2022 | 104 | $322.7M |
| Q1 2022 | 99 | $479.8M |
| Q4 2021 | 104 | $683.6M |
| Q3 2021 | 81 | $665.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Maxcyte, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| River & Mercantile Asset Management LLP | 1,708,348 | $8.40M | 1.72% | +60,110+3.6% | Added |
| State Street Corp | 1,794,149 | $8.88M | 0.00% | +2,582+0.1% | Added |
| Massachusetts Financial Services Co | 1,968,241 | $9.74M | 0.00% | +1820.0% | Added |
| Bamco Inc | 1,987,904 | $9.84M | 0.03% | −195,078−8.9% | Reduced |
| Holocene Advisors, LP | 2,117,228 | $10.5M | 0.05% | −620,382−22.7% | Reduced |
| ArrowMark Colorado Holdings LLC | 2,299,074 | $11.4M | 0.13% | +40,842+1.8% | Added |
| Stonepine Capital Management, LLC | 2,707,090 | $13.4M | 4.49% | +2,433,803+890.6% | Added |
| Millennium Management LLC | 2,847,153 | $14.1M | 0.02% | +948,640+50.0% | Added |
| Blue Water Life Science Advisors, LLC | 3,225,000 | $16.0M | 10.56% | 00.0% | Unchanged |
| Vanguard Group Inc | 4,888,473 | $24.2M | 0.00% | +40,356+0.8% | Added |
| Casdin Capital, LLC | 4,925,000 | $24.4M | 2.01% | −4,580,000−48.2% | Reduced |
| Vitruvian Partners LLP | 5,043,356 | $25.0M | 5.33% | 00.0% | Unchanged |
| BlackRock Inc. | 7,020,661 | $34.8M | 0.00% | +205,579+3.0% | Added |
| Bank of New York Mellon Corp | 333,887 | – | – | −4,395−1.3% | Reduced |
| Bank of Montreal | 3,974 | – | – | +3,974 | New |
| Pier Capital, LLC | 0 | $0 | 0.00% | −1,074,164−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −101,200−100.0% | Sold out |
| Advisory Research Inc | 0 | $0 | 0.00% | −27,204−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,018−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −44−100.0% | Sold out |
| North Run Capital, LP | – | – | – | – | Not filed |